Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study

Yu Nakamura,Jun Adachi,Naoki Hirota,Katsuhiro Iba,Koichi Shimizu,Masami Nakai,Kaneyoshi Takahashi,Naoki Mori

DOI: https://doi.org/10.1002/alz.14282

2024-10-07

Alzheimer s & Dementia

Abstract:INTRODUCTION We evaluated the efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia (AAD) in Japanese patients. METHODS This was a phase 2/3 multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Patients with AAD were randomized to receive brexpiprazole 1 mg/day or 2 mg/day, or placebo (3:4:4) for 10 weeks. RESULTS For the primary endpoint (change in Cohen‐Mansfield Agitation Inventory [CMAI] total score from baseline to Week 10), both brexpiprazole 1 mg and 2 mg groups demonstrated statistically significant improvement versus placebo (2 mg: least squares [LS] mean difference –7.2 [95% confidence interval (CI): –10.0 to –4.3], p‐value

clinical neurology